Trial
NCT02569801
A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Breast Cancer
Intervention
Fulvestrant
Why stopped
The Sponsor decided to halt the development of GDC-0810, but not due to any safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-04-23